Company news

Tiziana Life Sciences Ltd news in 2026

Tiziana Life Sciences Ltd's news releases, calls and decks from 2026, newest first.

View company

Tiziana to Host Investor Call with Key Opinion Leaders to Discuss Positive Phase 2a INFORM-MS Topline Results

November 5, 2026

Tiziana Announces Positive Topline Results from Phase 2a INFORM-MS Trial of Intranasal Foralumab in Non-Active Secondary Progressive Multiple Sclerosis

November 2, 2026

Tiziana Management Team to Attend the 10th Joint ACTRIMS-ECTRIMS Meeting in Toronto

October 21, 2026

Tiziana Doses Last Patient in Phase 2 Trial of Intranasal Foralumab for Mild Alzheimer’s Disease

October 16, 2026

Tiziana Life Sciences Files for Orphan Drug Designation with the FDA for Intranasal Foralumab for the Treatment of Multiple System Atrophy (MSA)

September 30, 2026

Tiziana Life Sciences Announces First Participants Dosed in ALS BANYAN Clinical Trial of Intranasal Foralumab

September 28, 2026

Tiziana Announces Last Patient Completes Last Visit in Phase 2a INFORM-MS Trial of Intranasal Foralumab

September 21, 2026

Tiziana Life Sciences Announces Signing of MOU with King Abdullah International Medical Research Center

September 17, 2026

Tiziana Life Sciences Announces Poster Presentation on Phase 2a BANYAN Clinical Trial of Intranasal Foralumab at ALS Nexus 2026

August 24, 2026

Tiziana Life Sciences Announces Purchase of Shares by Chief Executive Officer

August 6, 2026

Tiziana Reports Reduction in Brain Inflammation in Third Multiple System Atrophy Patient Treated with Intranasal Foralumab

July 31, 2026

Tiziana Life Sciences Announces Purchase of Shares by Executive Chairman

June 15, 2026

Tiziana Life Sciences to Present at the Jefferies Global Healthcare Conference in New York

May 28, 2026

Tiziana Fully Enrolls its Phase 2 Placebo Controlled Multiple Sclerosis Trial

May 21, 2026

Tiziana Announces New Positive Clinical Data for Intranasal Foralumab in Non-Active Secondary Progressive Multiple Sclerosis

May 18, 2026

Tiziana Reports Reduced Brain Inflammation in Multiple System Atrophy Patients Treated with Intranasal Foralumab

May 13, 2026

Tiziana Life Sciences Announces Publication of Positive Data Demonstrating Intranasal Anti-CD3 Antibody Attenuates Long COVID Neuroinflammation and Improves Cognitive Function

April 15, 2026

Tiziana Life Sciences Announces Late Breaking Poster Accepted for Presentation at the 7th World Parkinson Congress

April 13, 2026

Tiziana Announces Data Showing Nasal Anti-CD3 Improves Cognition Associated with Aging

March 31, 2026

Tiziana Life Sciences Announces New Biomarker Data Showing Nasal Foralumab Downregulates CSF Inflammation, Upregulates Neuroprotective Pathways, and Correlates with Reduced Microglial Activation on PET Scans in na-SPMS Patients with PIRA

February 24, 2026

Tiziana Life Sciences Announces the Peer-Reviewed Publication of Clinical Study Results for Intranasal Foralumab

January 20, 2026

Tiziana Life Sciences Announces Closing of Oversubscribed $8.8 Million Registered Direct Offering of Ordinary Shares

January 16, 2026

Tiziana Life Sciences Announces Registered Direct Offering of up to approximately $17.6 Million

January 16, 2026

Tiziana Life Sciences to Present at the 9th Annual Neuroscience Innovation Forum During J.P. Morgan Healthcare Conference Week in San Francisco

January 9, 2026

Decks in 2026